Albumin-Bound Paclitaxel clinical trials
Albumin-Bound Paclitaxel is named as an intervention in 37 current clinical trials in our China, USA, Germany, France, UK, Netherlands, Canada, Israel, Spain, Italy, Japan, South Korea and Singapore registers. 20 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Chinese PLA General Hospital (3). The most-studied condition is Pancreatic Cancer.
Patient leaflets for Albumin-Bound Paclitaxel
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Albumin-Bound Paclitaxel
37 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Albumin-Bound Paclitaxel
46 conditionsAll 46 conditions
| Condition (as registered) | Trials |
|---|---|
| Pancreatic Cancer | 5 |
| Gastric Cancer | 4 |
| Breast Cancer | 3 |
| Biliary Tract Cancer | 2 |
| Head and Neck Squamous Cell Carcinoma | 2 |
| Cervical Cancer | 2 |
| Neoadjuvant Therapy | 2 |
| Melanoma, Cutaneous Malignant | 1 |
| Mucosal Melanoma | 1 |
| Advanced Cancer | 1 |
| Gastroesophageal-junction Cancer | 1 |
| Salivary Gland Carcinoma | 1 |
| Precision Therapy | 1 |
| Tongue Squamous Cell Carcinoma | 1 |
| Squamous Cell Non-small Cell Lung Cancer | 1 |
| Advanced Pancreatic Cancers | 1 |
| Triple Negative Breast Cancer | 1 |
| Gastric Cancer Peritoneal Metastasis (GCPM) | 1 |
| HER2 Positive Advanced Solid Tumors | 1 |
| Oral Cancer | 1 |
| Advanced or Metastatic Solid Tumors | 1 |
| Esophageal Cancer | 1 |
| Chemoradiotherapy | 1 |
| Albumin-bound Paxlitaxel | 1 |
| Unresectable Malignant Neoplasm | 1 |
| Solid Cancer | 1 |
| Neoadjuvant Chemotherapy | 1 |
| Bulky Neoplasm | 1 |
| Oral Squamous Cell Carcinoma | 1 |
| Oropharyngeal Squamous Cell Carcinoma | 1 |
| Esophageal Squamous Cell Carcinoma (ESCC) | 1 |
| Second-line Treatment | 1 |
| Early Breast Cancer | 1 |
| TNBC, Triple Negative Breast Cancer | 1 |
| Second Line Treatment | 1 |
| Chemotherapy | 1 |
| Tyrosine Kinase Inhibitor | 1 |
| GC/GEJC | 1 |
| Gastroesophageal Junction Adenocarcinoma | 1 |
| Uterine Cervical Neoplasm | 1 |
| Uterine Cervical Cancer | 1 |
| Non-small Cell Lung Cancer | 1 |
| Locally Advanced Cervical Cancer | 1 |
| Solid Tumor | 1 |
| Triple-negative Breast Cancer | 1 |
| Carcinoma, Non-Small-Cell Lung | 1 |
Sponsors
lead sponsor per trial+ 15 more sponsors in the trial list above.
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Albumin-Bound Paclitaxel trials
How many clinical trials are testing Albumin-Bound Paclitaxel?
37 current trials in our China, USA, Germany, France, UK, Netherlands, Canada, Israel, Spain, Italy, Japan, South Korea and Singapore registers name Albumin-Bound Paclitaxel (also registered as 2 cycles) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Albumin-Bound Paclitaxel trials recruiting patients?
Yes. 20 of the 37 trials are recruiting: 19 with sites in China, 1 with sites in USA, 1 with sites in Germany, 1 with sites in France, 1 with sites in UK, 1 with sites in Netherlands, 1 with sites in Canada and 1 with sites in Israel. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Albumin-Bound Paclitaxel clinical trials?
Chinese PLA General Hospital (3), Sun Yat-sen University (3), Tianjin Medical University Cancer Institute and Hospital (2) and Tang-Du Hospital (2), among 30 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Albumin-Bound Paclitaxel works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Albumin-Bound Paclitaxel works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Albumin-Bound Paclitaxel (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.